Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Proteome Sciences PLC

Healthcare GB PRM

1.6GBX
-0.205(11.36%)

Last update at 2026-06-05T15:35:00Z

Day Range

1.602.00
LowHigh

52 Week Range

1.304.40
LowHigh

Fundamentals

  • Previous Close 1.80
  • Market Cap5.52M
  • Volume23471
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.13500M
  • Revenue TTM4.53M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 0.79M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -3.24800M -2.41800M 1.25M 0.12M 0.24M
Minority interest - - - - -
Net income -3.40600M -2.44300M 1.32M 0.07M 0.29M
Selling general administrative 3.02M 3.27M 3.04M 2.55M 2.04M
Selling and marketing expenses - 585.00M - - -
Gross profit -0.16700M 1.16M 4.77M 2.96M 2.58M
Reconciled depreciation 0.84M 0.48M 0.11M 0.21M 0.17M
Ebit -2.27400M -1.47000M 1.73M 0.41M 0.55M
Ebitda -1.43700M -0.98600M 1.83M 0.62M 0.71M
Depreciation and amortization 0.84M 0.48M 0.11M 0.21M 0.17M
Non operating income net other - - - - -
Operating income -2.27400M -1.47000M 1.73M 0.41M 0.55M
Other operating expenses 7.16M 6.50M 6.05M 4.72M 4.20M
Interest expense 0.90M 0.80M 0.47M 0.29M 0.30M
Tax provision 0.16M 0.03M -0.07000M 0.05M -0.05000M
Interest income - - - - 0.30M
Net interest income -0.89500M -0.79700M -0.47300M -0.29400M -0.30400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.16M 0.03M -0.07000M 0.05M -0.05000M
Total revenue 4.89M 5.03M 7.78M 5.13M 4.75M
Total operating expenses 2.11M 2.63M 3.04M 2.55M 2.04M
Cost of revenue 5.05M 3.87M 3.01M 2.17M 2.17M
Total other income expense net -0.97400M -0.94800M -0.47300M -0.29400M -0.30400M
Discontinued operations - - - - -
Net income from continuing ops -3.40500M -2.44300M 1.32M 0.07M 0.29M
Net income applicable to common shares - - - 0.07M 0.29M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 9.21M 11.46M 12.43M 10.04M 9.09M
Intangible assets - 3617.00M - - -
Earning assets - - - - -
Other current assets 0.22M 0.25M - 1.08M 1.25M
Total liab 15.72M 14.52M 13.28M 12.82M 12.45M
Total stockholder equity -6.51600M -3.06600M -0.84300M -2.77500M -3.35800M
Deferred long term liab - - - - -
Other current liab 0.14M 0.18M 0.10M 0.05M 0.15M
Common stock 2.95M 2.95M 2.95M 2.95M 2.95M
Capital stock 2.95M 2.95M 2.95M 2.95M 2.95M
Retained earnings -76.34900M -72.94200M -70.54200M -72.01300M -72.06300M
Other liab - - - 0.50M 0.49M
Good will 4.22M 4.22M 4.22M 4.22M 4.22M
Other assets - 0.00000M - - -
Cash 1.13M 2.03M 3.99M 2.39M 2.21M
Cash and equivalents - - - - -
Total current liabilities 14.01M 12.47M 12.49M 11.72M 11.96M
Current deferred revenue - 0.00100M - 0.04M -
Net debt 13.39M 11.45M 7.92M 9.25M 8.83M
Short term debt 13.23M 11.84M 11.56M 11.03M 11.04M
Short long term debt 12.63M 11.23M 11.26M 10.82M 10.55M
Short long term debt total 14.52M 13.47M 11.91M 11.63M 11.04M
Other stockholder equity 51.47M 62.22M 66.75M 66.29M 65.75M
Property plant equipment - - - 1.27M 0.54M
Total current assets 2.59M 4.16M 6.90M 4.56M 4.33M
Long term investments - - - - -
Net tangible assets - - - -6.99300M -7.57600M
Short term investments - - - - -
Net receivables 0.51M 1.05M 1.44M 0.60M 1.19M
Long term debt 0.25M 0.00000M - - -
Inventory 0.73M 0.84M 0.90M 1.09M 0.88M
Accounts payable 0.64M 0.45M 0.82M 0.60M 0.77M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 15.41M 4.70M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 2.95M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00100M 11209.00M -0.00100M -0.00100M -
Deferred long term asset charges - - - - -
Non current assets total 6.62M 7.29M 5.54M 5.49M 4.76M
Capital lease obligations 1.64M 2.24M 0.65M 0.81M 0.49M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.22400M -0.42400M -0.31900M -0.20400M -0.01300M
Change to liabilities - - 0.00000M -0.28700M 0.16M
Total cashflows from investing activities -0.22400M -0.42400M - -0.20400M -0.01300M
Net borrowings 0.75M -0.82400M - -0.40000M -0.14600M
Total cash from financing activities 0.15M -1.06200M -0.20900M -0.40000M -0.14600M
Change to operating activities - - - 0.00700M 0.09M
Net income -3.40600M -2.44300M 1.32M 0.07M 0.24M
Change in cash -0.89900M -1.96700M 1.61M 0.18M 1.41M
Begin period cash flow 2.03M 3.99M 2.39M 2.21M 0.80M
End period cash flow 1.13M 2.03M 3.99M 2.39M 2.21M
Total cash from operating activities -0.82600M -0.48100M 2.14M 0.79M 1.58M
Issuance of capital stock - - - - -
Depreciation 0.84M 0.48M 0.11M 0.21M 0.17M
Other cashflows from investing activities - -0.18700M - - -
Dividends paid - 2195.00M - - -
Change to inventory 0.10M 0.06M 0.19M -0.21100M -0.00600M
Change to account receivables 0.57M 0.70M - 0.16M 0.57M
Sale purchase of stock - -5249.00000M - - -
Other cashflows from financing activities -0.59900M -0.23800M -0.31900M -0.20400M -0.01300M
Change to netincome - - 0.78M 0.84M 0.31M
Capital expenditures 0.22M 0.24M 0.32M 0.20M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.83M 0.45M -0.36000M -0.32900M 0.81M
Stock based compensation 0.04M 0.22M 0.30M 0.57M 0.00800M
Other non cash items 0.88M 0.81M 0.77M 0.27M 0.30M
Free cash flow -1.05000M -0.71800M 1.82M 0.59M 1.57M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PRM
Proteome Sciences PLC		 -0.205 11.36% 1.60 - - 1.22 - 4.57 14.51
IDHC
Integrated Diagnostics Holdings PLC		 0.02 3.77% 0.55 0.20 12.89 3.33 6.89 3.22 8.79
HVO
hVIVO plc		 0.45 5.36% 8.85 7.05 18.32 0.89 1.01 0.69 2.93
ABDX
Abingdon Health Plc		 -0.75 5.88% 12.00 - 53.19 2.19 3.19 1.81 -0.2499
CLBX
CelLBxHealth plc		 -0.125 6.49% 1.80 - - 7.05 1.50 6.07 -1.6211

Reports Covered

Stock Research & News

View All

Profile

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also offers top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, as well as to academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

Proteome Sciences PLC

Coveham House, Cobham, United Kingdom, KT11 3EP

Key Executives

Name Title Year Born
Dr. Mariola Sohngen CEO & Exec. Director 1961
Dr. Ian H. Pike Chief Scientific Officer & Exec. Director NA
Mr. Richard Paul Dennis Chief Commercial Officer & Exec. Director 1959
Mr. Abdelghani Omari CFO & Director 1977
Mr. Glenn Barney VP of Sales & Marketing NA
Victoria Birse Company Sec. NA
Mr. Christopher Donovan James Pearce Dip., MSI Executive Chairman 1953
Dr. Ian Hugo Pike Chief Scientific Officer & Executive Director 1964
Mr. Richard Paul Dennis Chief Commercial Officer & Executive Director 1958
Victoria Joanna Birse Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions